Table 3. One-year clinical outcomes in all patients.
| Outcomes | SS PCI (n=254) | MS PCI (n=352) | Univariate | Multivariate | |||
|---|---|---|---|---|---|---|---|
| HR (95% CI)* | p value | HR (95% CI)† | p value | ||||
| 30 days outcomes | |||||||
| MACE§ | 22/254 (8.7) | 15/352 (4.3) | 0.48 (0.25–0.93) | 0.025 | 0.94 (0.44–1.99) | 0.864 | |
| All-cause mortality | 17/254 (6.7) | 6/352 (1.7) | 0.25 (0.10–0.63) | 0.001 | 0.62 (0.20–1.95) | 0.409 | |
| Cardiac death | 13/254 (5.1) | 5/352 (1.4) | 0.27 (0.10–0.76) | 0.008 | 0.53 (0.14–1.97) | 0.344 | |
| 30 days to 1-year outcomes‡ | |||||||
| MACE§ | 21/232 (9.1) | 21/337 (6.2) | 0.65 (0.35–1.20) | 0.164 | 0.65 (0.34–1.25) | 0.196 | |
| All-cause mortality | 10/237 (4.2) | 6/346 (1.7) | 0.40 (0.15–1.11) | 0.068 | 0.35 (0.11–1.08) | 0.068 | |
| Cardiac death | 6/241 (2.5) | 3/347 (0.9) | 0.34 (0.08–1.34) | 0.105 | 0.23 (0.04–1.18) | 0.078 | |
| 1-year outcomes | |||||||
| MACE§ | 43/254 (16.9) | 36/352 (10.2) | 0.56 (0.36–0.88) | 0.012 | 0.74 (0.46–1.21) | 0.230 | |
| All-cause mortality | 27/254 (10.6) | 12/352 (3.4) | 0.31 (0.16–0.60) | 0.001 | 0.42 (0.19–0.92) | 0.030 | |
| Cardiac death | 19/254 (7.5) | 8/352 (2.3) | 0.29 (0.13–0.67) | 0.003 | 0.42 (0.16–1.06) | 0.066 | |
| Non-cardiac death | 8/254 (3.1) | 4/352 (1.1) | 0.34 (0.10–1.13) | 0.079 | 0.87 (0.19–4.11) | 0.873 | |
| Myocardial infarction | 7/254 (2.8) | 13/352 (3.7) | 1.28 (0.51–3.21) | 0.598 | 1.47 (0.52–4.41) | 0.464 | |
| TVR/TLR | 8/254 (3.1) | 11/352 (3.1) | 0.92 (0.37–2.29) | 0.859 | 0.91 (0.34–2.43) | 0.851 | |
| Definite stent thrombosis | 4/254 (1.6) | 7/352 (2.0) | 1.29 (0.38–4.41) | 0.685 | 1.07 (0.28–4.12) | 0.919 | |
| Stroke | 5/254 (2.0) | 3/352 (0.9) | 0.42 (0.10–1.74) | 0.228 | 0.20 (0.04–1.13) | 0.069 | |
Values are number (%) for categorical values.
MACE = major adverse cardiovascular event; MS PCI = multi-staged percutaneous coronary intervention; SS PCI = single-staged percutaneous coronary intervention; TLR = target lesion revascularization; TVR = target vessel revascularization.
*HR are for the multi-vessel MS PCI groups compared with multi-vessel SS PCI group; †Adjusted Cox hazard regression analysis included age, sex, medications (statin, glycoprotein IIb/IIIa inhibitor), initial heart rate, left ventricular ejection fraction, pre TIMI flow (0–1 vs. 2–3), Initial Killip class (I–II vs. III–IV), infarct related vessel (IRA), treatment of IRA lesion, number of vessel disease; ‡Subjects who had an adverse events in initial 30 days were excluded in 30 days to 1-year outcomes data. Cox hazard regression analysis also included same variables used in 30 days outcomes and 1-year outcomes; §MACE defined as a composite of all-cause death, myocardial infarction, stroke, TVR, TLR, stent thrombosis.